DPP-4 Inhibitors for Glycemic Control in Advanced Diabetes
Solution Overview
Problem
Current treatments for type 2 diabetes, particularly in advanced or late stages, face challenges with maintaining long-term glycemic control, often resulting in secondary drug failures and increased risk of adverse effects, such as hypoglycemia and weight gain, especially in patients with renal impairment or those ineligible for metformin therapy.
Innovation Solution
The use of DPP-4 inhibitors, such as sitagliptin, vildagliptin, and saxagliptin, either alone or in combination with other antidiabetic drugs, to improve glycemic control and reduce the risk of secondary drug failures and adverse effects in patients with inadequate response to conventional therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional combination therapy is used to enhance glycemic control, then blood glucose levels are reduced initially, but long-term efficacy deteriorates and hypoglycemia risk increases
Solution Approach 1:
The patent introduces DPP-4 inhibitors as a new therapeutic parameter that modifies the glycemic control mechanism. These inhibitors work by blocking the degradation of GLP-1, thereby enhancing insulin secretion in a glucose-dependent manner, which provides sustained glycemic control without the hypoglycemia risk associated with traditional combination therapies.
2Reliability
If multiple antihyperglycemic drugs are combined to achieve better glycemic control, then blood glucose is reduced, but patient compliance decreases due to medication complexity
Solution Approach 1:
The patent segments the therapeutic approach by identifying DPP-4 inhibitors as a distinct class that can be used either as monotherapy or in combination with other agents. This segmentation allows patients to receive simplified single-agent therapy when appropriate, improving compliance while maintaining efficacy.
3Reliability
If conventional oral antidiabetic drugs are used, then glycemic control is achieved initially, but secondary drug failure occurs over time
Solution Approach 1:
The patent emphasizes the continuous action of DPP-4 inhibitors through their mechanism of blocking GLP-1 degradation. This results in sustained insulin secretion and prolonged glycemic control, preventing the secondary drug failure that occurs with conventional oral antidiabetic drugs.
4Reliability
If multiple medications are prescribed to control advanced diabetes, then glycemic control is improved, but pharmacokinetic interactions with other medications increase
Solution Approach 1:
The patent positions DPP-4 inhibitors as an intermediary therapeutic option that can be integrated into existing treatment regimens. These inhibitors have a favorable pharmacokinetic profile with minimal drug-drug interactions, making them suitable for patients on multiple medications while maintaining effective glycemic control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DPP-4 inhibitors effectively lower HbA1c and glucose levels, improve insulin secretion, and reduce the risk of adverse effects, offering a safer and more tolerable alternative for patients with insufficient glycemic control despite conventional antidiabetic therapies, including those with renal impairment.
Implementation Method 1
DPP-4 inhibitors interfere with the plasma level of bioactive peptides including the peptide GLP-1
Data Source
AI summary
The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.